NASDAQ:NTLA

Intellia Therapeutics Stock News

Healthcare > Biotechnology

Buy NTLA

*Your capital is at risk

$14.75

+1.73 (+13.29%)

At Close: Jun 04, 2026

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLA

11:15am, Wednesday, 22'nd Jan 2025

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA). Such invest

NTLA ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Intellia Therapeutics, Inc. Shareholders Who Lost Money

10:30am, Wednesday, 22'nd Jan 2025

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NT

Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Stockholders to Inquire about Securities Investigation

10:00am, Wednesday, 22'nd Jan 2025

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

07:30am, Wednesday, 22'nd Jan 2025

CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera

Intellia Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - NTLA

10:30am, Tuesday, 21'st Jan 2025

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NT

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Investors to Learn More About the Investigation

10:00am, Tuesday, 21'st Jan 2025

NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the

NTLA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Intellia Therapeutics, Inc. investment

11:00am, Monday, 20'th Jan 2025

NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NT

Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

10:00am, Monday, 20'th Jan 2025

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Intellia Therapeutics, Inc. (NTLA)

10:13am, Sunday, 19'th Jan 2025

NEW YORK, NY / ACCESSWIRE / January 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) c

NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Intellia Therapeutics, Inc. and Encourages Investors to Contact the Firm

10:00am, Sunday, 19'th Jan 2025

NEW YORK CITY, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the

Lost Money on Intellia Therapeutics, Inc.(NTLA)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

06:01pm, Saturday, 18'th Jan 2025

NEW YORK, NY / ACCESSWIRE / January 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) c

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLA

12:00pm, Saturday, 18'th Jan 2025

NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA). Such invest

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

02:36pm, Friday, 17'th Jan 2025

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

12:20pm, Friday, 17'th Jan 2025

Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despi

Intellia Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NTLA

11:15am, Friday, 17'th Jan 2025

NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NT

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by